Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease.
作者信息
Sperandio da Silva Gilberto Marcelo
机构信息
Fundação Oswaldo Cruz-Fiocruz.
出版信息
Mem Inst Oswaldo Cruz. 2022 Jul 8;117:e210034chgsa. doi: 10.1590/0074-02760210034chgsa. eCollection 2022.
Abstract
摘要
相似文献
1
Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease.传统上使用苯硝唑并每周进行临床随访表明是恰加斯病病因治疗的重要方法。
Mem Inst Oswaldo Cruz. 2022 Jul 8;117:e210034chgsa. doi: 10.1590/0074-02760210034chgsa. eCollection 2022.
2
An update on benznidazole for the treatment of patients with Chagas disease.用于治疗恰加斯病患者的苄硝唑最新情况。
Drugs Today (Barc). 2018 Jan;54(1):15-23. doi: 10.1358/dot.2018.54.1.2753402.
3
Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).用于晚期有症状的恰加斯病（克氏锥虫感染）的杀锥虫药物。
Cochrane Database Syst Rev. 2020 Dec 11;12(12):CD004102. doi: 10.1002/14651858.CD004102.pub3.
4
Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.患者摘要。用苯硝唑治疗非急性恰加斯病的长期结果。
Ann Intern Med. 2006 May 16;144(10):I32. doi: 10.7326/0003-4819-144-10-200605160-00002.
5
The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.苯硝唑与氰钴胺和抗坏血酸在治疗恰加斯病慢性期的作用。
Rev Soc Bras Med Trop. 2014 Sep-Oct;47(5):669. doi: 10.1590/0037-8682-0089-2014.
6
Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.慢性恰加斯病患者在 4 年药物治疗随访中的临床和血清学演变：一项初步研究。
Rev Soc Bras Med Trop. 2013 Nov-Dec;46(6):776-8. doi: 10.1590/0037-8682-1646-2013.
7
Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.慢性恰加斯病患者的理想苄硝唑剂量方案：一项系统评价
Rev Inst Med Trop Sao Paulo. 2020;62:e52err. doi: 10.1590/s1678-9946202062052err. Epub 2020 Aug 21.
8
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.苯硝唑和泊沙康唑消除无症状 T. cruzi 携带者寄生虫：STOP-CHAGAS 试验。
J Am Coll Cardiol. 2017 Feb 28;69(8):939-947. doi: 10.1016/j.jacc.2016.12.023.
9
Should benznidazole be used in chronic Chagas' disease?苯硝唑是否应用于慢性恰加斯病？
Lancet. 1997 Mar 1;349(9052):653. doi: 10.1016/S0140-6736(05)61604-2.
10
Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.在实验性恰加斯病的慢性期用苄硝唑治疗可减少心脏病变。
Antimicrob Agents Chemother. 2005 Apr;49(4):1521-8. doi: 10.1128/AAC.49.4.1521-1528.2005.
本文引用的文献
1
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.苯达唑单药及联合福沙韦仑治疗恰加斯病的新方案（BENDITA）：一项 2 期、双盲、随机试验。
Lancet Infect Dis. 2021 Aug;21(8):1129-1140. doi: 10.1016/S1473-3099(20)30844-6. Epub 2021 Apr 6.
2
Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.苯硝唑可降低慢性恰加斯病进展和心血管事件的风险：一项长期随访研究。
EClinicalMedicine. 2020 Dec 23;31:100694. doi: 10.1016/j.eclinm.2020.100694. eCollection 2021 Jan.
3
Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.苯达唑治疗安全性：无国界医生组织在玻利维亚大量恰加斯病患者中的经验。
J Antimicrob Chemother. 2017 Sep 1;72(9):2596-2601. doi: 10.1093/jac/dkx180.
4
2 nd Brazilian Consensus on Chagas Disease, 2015.2015年第二届巴西恰加斯病共识
Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60. doi: 10.1590/0037-8682-0505-2016.
Zotero 插件